FIG 7.

Predicting the host response to treatment via skin microbiota. (a and b) Distribution (left) and density (right) of MiSH (a) and SCORAD (b) in the 18 patients at baseline. The MiSH, but not SCORAD, exhibits a multimodal (bimodal) distribution, suggesting patient stratification into distinct disease state prior to treatment, despite their equivalent SCORAD. (c) AD-active children were classified based on their baseline skin microbiota into types I and II, with their organismal signatures shown as a heatmap. (d) Pre- and posttreatment MiSH for the types I and II of patients. The SCORAD index is also shown for comparison purposes.